Canagliflozin Reduces Cardiorenal Biomarkers in T2D

WEDNESDAY, Aug. 23, 2023 -- For people with type 2 diabetes and albuminuria, canagliflozin reduces the longitudinal trajectory of increase in cardiorenal biomarkers, according to a study published online Aug. 22 in Circulation. James L. Januzzi,...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news